Cidara Therapeutics (CDTX) announced the publication of preclinical data assessing CD388, the company’s influenza DFC, in the peer-reviewed ...

Catani and colleagues provide data on antigenic properties of neuraminidase proteins of pandemic H1N1 and show that antigenic diversity of the neuraminidase from 2009 to 2020 largely falls into two ...

“As oseltamivir is the most widely used therapeutic and prophylactic against IAV, the continued circulation of viruses harboring NA-H275Y may necessitate a re-evaluation of influenza treatment ...

Aims In this study, we analyze the challenges involved in detecting novel neuraminidase inhibitors (NAIs) and offer strategies to overcome them with complementary bioassays. Materials & Methods We ...

Schmidt remarked on the drug's ability to target neuraminidase, a key receptor for the influenza virus, suggesting that CD388 could become a significant preventative treatment for a wide array of ...

Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune statusSAN DIEGO, March 17, ...